Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04958434 · ClinicalTrials.gov registry record · Phase 1
Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Suzhou Transcenta Therapeutics Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04958434: Clinical Trial Phase 1 study, sponsored by Suzhou Transcenta Therapeutics Co..
NCT04958434 is a Phase 1 study that was terminated before completion, run by Suzhou Transcenta Therapeutics Co.. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04958434, a Phase 1 study, was terminated before completion, sponsored by Suzhou Transcenta Therapeutics Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is an open label Phase 1, first-in-human (FIH) study of TST005, a bi-specific antibody consisting of a PD-L1 monoclonal antibody (mAb) and a transforming growth factor beta (TGF-β) trap in subjects with locally advanced or metastatic cancers
Primary Outcome
As measured by the number of participants experiencing a dose limiting toxicity (DLT) in each dosing cohort
Interventions
- DRUG TST005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2023-09-30 |
| Phase | Phase 1 |
Why NCT04958434 stopped before completion
NCT04958434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which TST005 is the first listed.
NCT04958434 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04958434 about?
NCT04958434 is a clinical study titled "Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors". This is an open label Phase 1, first-in-human (FIH) study of TST005, a bi-specific antibody consisting of a PD-L1 monoclonal antibody (mAb) and a transforming growth factor beta (TGF-β) trap in subjects with locally advanced or metastatic cancers
What is the current status of trial NCT04958434?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2021-06-11. Estimated completion is 2023-09-30.
What interventions are being tested in trial NCT04958434?
The interventions under investigation include: TST005 (DRUG).
Who is sponsoring clinical trial NCT04958434?
This trial is sponsored by Suzhou Transcenta Therapeutics Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04958434's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI